Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population
Completed
Novo Nordisk A/S
Phase 3
2002-06-01
This trial is conducted in the United States of America (USA). The aim of this trial is to to
determine whether insulin aspart can be used effectively and safely in paediatric patients.
The Association Between Peri-Operative Hyperglycemia and Major Morbidity and Mortality
Terminated
University of Medicine and Dentistry of New Jersey
N/A
2007-06-01
Surgery induces a stress effect on the body partially through a catabolic energy state. In
turn, glucose levels may rise to levels which have been associated with major morbidity
(Golden, 1999) and mortality (Ouattara, 2005). An increasing body of evidence suggests that
intensive insulin therapy for tight control of blood glucose levels in certain surgical and
critical care patient populations may improve mortality and selected morbidity outcomes when
compared to those patients receiving conventional insulin therapy and blood glucose
management. More specifically, poor intra-operative blood glucose control is associated with
worse outcome after cardiac surgery. Intensive insulin therapy with tight blood glucose
control in surgical patients while in the ICU may reduce morbidity and mortality. Such
outcome improvements would clearly provide benefits to patients, providers and payers. To
date, there is scant research examining whether intensive insulin therapy for tight control
of blood glucose in the perioperative period can alter outcomes for the non cardiac surgery
population. The purpose of this study is to determine whether intensive insulin therapy for
tight control of blood glucose in the perioperative period in non cardiac major surgery
patients is associated with altered morbidity and mortality rates.
Comparison of a Twice Daily Versus a Three Times Daily Insulin Regimen in Children With Type 1 Diabetes
Completed
University of Calgary
N/A
2008-03-01
The purpose of this study is to determine whether there is a difference in blood sugar
control (as measured by hemoglobin A1c (HA1c)), in children given twice daily insulin
injections incorporating a new long acting insulin analogue (detemir) compared to children
using their current three times a day insulin injections (with intermediate and rapid acting
insulin).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
